Drugs / RENVISTOBART
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04150965 | Jul 2020 → Aug 2024 | plasma cell myeloma, refractory plasma cell neoplasm | Multiple Myeloma Research Consortium | Terminated | No outcome recorded |
| Phase 1/2 | NCT02913313 | Nov 2016 → Jan 2024 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05005273 | Oct → Dec 2022 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04570839 Background | Aug 2020 → May 2024 | endometrium neoplasm, head and neck cancer, ovarian cancer | Compugen Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RENVISTOBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297707 ↗ |
| Known as | BMS-986207 | “Anti-TIGIT (BMS-986207)” NCT04150965 ↗ |
| Action | Inhibit | “BMS-986207 (an inhibitor of TIGIT)” NCT04570839 ↗ |
| Modality | Monoclonal antibody | “Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors” NCT02913313 ↗ |
| Route | Intravenous | “All study drugs will be administered IV every 4 weeks” NCT04570839 ↗ |
| Target | TIGIT | “BMS-986207 (an inhibitor of TIGIT)” NCT04570839 ↗ |